Eyepoint Pharmaceuticals, INC 8-K filings

EyePoint Pharmaceuticals reported positive interim data from its Phase 2 VERONA trial, showing significant improvements in vision and retinal thickness for DURAVYU in patients with diabetic macular edema.

EyePoint Pharmaceuticals has dosed the first patient in its Phase 3 LUGANO clinical trial for DURAVYU, a potential treatment for wet age-related macular degeneration.

EyePoint Pharmaceuticals appoints Fred Hassan to its Board of Directors following the resignation of two members, as the company prepares for Phase 3 trials of its lead product candidate.

EyePoint Pharmaceuticals announced positive clinical trial results for DURAVYU and its second quarter 2024 financial results, highlighting progress in its pipeline and financial position.

EyePoint Pharmaceuticals announced positive 12-month results from its Phase 2 DAVIO 2 trial for DURAVYU in wet AMD and detailed plans for Phase 3 trials.

EyePoint Pharmaceuticals' stockholders approved amendments to the company's long-term incentive and employee stock purchase plans, along with electing directors at the 2024 Annual Meeting.

EyePoint Pharmaceuticals is advancing its pipeline, highlighted by positive Phase 2 results for DURAVYU in wet AMD and plans to initiate Phase 3 trials in the second half of 2024.

EyePoint Pharmaceuticals announced its first quarter 2024 financial results, highlighting progress in its clinical pipeline, particularly with DURAVYU for retinal diseases.

EyePoint Pharmaceuticals' Phase 2 PAVIA trial of DURAVYU for non-proliferative diabetic retinopathy showed stable or improved disease severity and reduced progression rates at nine months, though the primary endpoint was not met.

EyePoint Pharmaceuticals reported positive topline data from its Phase 2 DAVIO 2 trial for EYP-1901 in wet AMD, along with financial results for the fourth quarter and full year 2023.

EyePoint Pharmaceuticals has appointed Ramiro Ribeiro, M.D., Ph.D., as its new Chief Medical Officer, effective March 1, 2024, while also progressing its clinical trials for retinal disease treatments.